{Reference Type}: Journal Article
{Title}: Changes over 24 years in a pregnancy register - Teratogenicity and epileptic seizure control.
{Author}: Vajda F;O'Brien T;Graham J;Hitchcock A;Perucca P;Lander C;Eadie M;
{Journal}: Epilepsy Behav
{Volume}: 148
{Issue}: 0
{Year}: 2023 Nov 13
{Factor}: 3.337
{DOI}: 10.1016/j.yebeh.2023.109482
{Abstract}: <B>OBJECTIVE: </B>To trace (i) changes in Australian Pregnancy Register (APR) records concerning antiseizure medications (ASMs) prescribed for women with epilepsy (WWE) over the course of 24 years and correlate the changes with (ii) rates of occurrence of pregnancies involving foetal malformations, (iii) the body organs involved in the malformations, and (iv) freedom from epileptic seizures.<BR><B>RESULTS: </B>Use of valproate and carbamazepine decreased progressively, use of lamotrigine remained relatively static, and the use of levetiracetam increased progressively, whereas the use of topiramate first increased and then fell again, associated with a temporary increase in malformation-associated pregnancy rate. More serious malformations, such as spina bifida, became less frequent, whereas more trivial ones tended to increase, whereas epileptic seizure freedom rates improved.<BR><B>CONCLUSIONS: </B>The increasing use of newer ASMs in pregnant women has been associated with overall advantages in relation to the frequency and severity of foetal malformation and with advantages in relation to freedom from epileptic seizures.